Integrated Wealth Concepts LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Integrated Wealth Concepts LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,524 shares of the medical research company’s stock after purchasing an additional 2,361 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Thermo Fisher Scientific were worth $4,274,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TMO. California State Teachers Retirement System lifted its position in shares of Thermo Fisher Scientific by 49,331.5% in the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock worth $141,711,778,000 after buying an additional 282,082,924 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares in the last quarter. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $15,501,867,000. Corient Private Wealth LP purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at $382,547,000. Finally, Norges Bank bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $3,072,744,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.3%

Shares of TMO opened at $610.97 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company’s fifty day simple moving average is $580.40 and its 200-day simple moving average is $518.55. The company has a market cap of $225.90 billion, a P/E ratio of 32.87, a P/E/G ratio of 2.55 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm posted $4.28 EPS. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Analysts Set New Price Targets

Several research firms have commented on TMO. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday. Barclays increased their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Finally, BMO Capital Markets lowered Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $624.64.

Insiders Place Their Bets

In related news, CEO Marc Casper sold 275 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last quarter. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.